financetom
Business
financetom
/
Business
/
Chainalysis Buys Israeli Fraud Detection Startup Alterya for $150M
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Chainalysis Buys Israeli Fraud Detection Startup Alterya for $150M
Jan 13, 2025 11:43 AM

Blockchain analytics company Chainalysis said Monday it had acquired fraud detection startup Alterya. The deal carried a price tag of $150 million, according to Business Insider.

Chainalysis, the largest company tracing illicit crypto flows on behalf of financial institutions and governments, plans to bolster its scam-stopping capabilities with Alterya, CEO Jonathan Levin told CoinDesk.

The two companies attack a thematically similar problem – bad actors on the blockchain – from different positions. Chainalysis amasses troves of intel on crypto wallets to trace where money is moving. Alterya, meanwhile, uses data on scammers to nix their transactions mid-route.

"Alterya has collected the most comprehensive set of information about all of the scammers' financial infrastructure that's out there," Levin said. Exchanges that plug into its dataset can flag transactions initiated by potential victims, stopping the crime before it happens.

Chainalysis already collects reams of data about crypto scammers, and there's significant overlap between its in-house blacklist and Alterya's, Levin said. But the startup's got an even bigger list than that of Chainalysis. By combining the two companies' capabilities, he expects to sniff out yet more scammers.

The acquisition continues Chainalysis' poaching of Israeli-based crypto security startups, after last month's buyout of Hexagate. All teams will work out of a new, combined office in Tel Aviv, Levin said. That could position the company well to further tap what he called Israel's "very deep talent market for this kind of work."

While Chainalysis is best-known for its work in the cryptospace, it is now moving to combat financial fraud more broadly. Alterya's AI driven fraud models have "substantial opportunities in the traditional market," Levin said, and the requisite data to help banks and other financial institutions stop fraud.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Hormel Foods Keeps Quarterly Dividend at $0.2825 a Share, Payable May 15 to Shareholders of Record April 15
--Hormel Foods Keeps Quarterly Dividend at $0.2825 a Share, Payable May 15 to Shareholders of Record April 15
Mar 25, 2024
05:09 PM EDT, 03/25/2024 (MT Newswires) -- Price: 34.19, Change: -0.03, Percent Change: -0.09 ...
Forza Lithium Announces The Closing Of Planet Green Metals Inc. Merger
Forza Lithium Announces The Closing Of Planet Green Metals Inc. Merger
Mar 25, 2024
05:09 PM EDT, 03/25/2024 (MT Newswires) -- Forza Lithium Corp. (FZ.CN) announced Monday that it has closed the acquisition of all the issued and outstanding shares of Planet Green Metals Inc. in consideration for, among other things, the issuance of 11.3 million common shares of Forza to the shareholders of Planet Green. The shares are subject to a statutory hold...
InnoCan Pharma
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval
Mar 25, 2024
05:05 PM EDT, 03/25/2024 (MT Newswires) -- Innocan Pharma Corporation ( INNPF ) , a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, announced Monday the signing of an agreement with the Hebrew University, which facilitate Innocan to initiate the Food and Drug Administration (FDA) approval process for its liposome CBD platform...
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing
Mar 25, 2024
05:06 PM EDT, 03/25/2024 (MT Newswires) -- Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer, on March 21, 2024, sold 14,491 shares in Supernus Pharmaceuticals ( SUPN ) for $511,677. Following the Form 4 filing with the SEC, Bhatt has control over a total of 8,570 shares of the company, with 8,570 shares held directly....
Copyright 2023-2026 - www.financetom.com All Rights Reserved